These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7131761)

  • 21. [A multicenter study on panipenem/betamipron in dermatology].
    Arata J; Akiyama H; Kanzaki H; Takahashi H; Tanaka Y; Takahama H; Fujimura M; Kushibuchi S; Ishibashi Y; Ihn H
    Jpn J Antibiot; 1992 Feb; 45(2):197-207. PubMed ID: 1613973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clindamycin-2-phosphate in the field of dermatology (author's transl)].
    Arata J; Yamamoto Y; Suwaki M; Nohara N
    Jpn J Antibiot; 1977 Jan; 30(1):114-6. PubMed ID: 839635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fundamental and clinical evaluations of cefmetazole against dermal infections by S. aureus (author's transl)].
    Watanabe Y; Yokoyama M; Itoh K; Yamada K
    Jpn J Antibiot; 1982 Jan; 35(1):261-7. PubMed ID: 6951062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The resistance of S aureus to aminoglycoside antibiotics and pristinamycins in France in 1976-1977.
    Le Goffic F
    Jpn J Antibiot; 1977 Dec; 30 Suppl():286-91. PubMed ID: 612709
    [No Abstract]   [Full Text] [Related]  

  • 25. [Aminoglycosides in pediatrics].
    Truckenbrodt H
    Adv Clin Pharmacol; 1978; 15():141-8. PubMed ID: 676873
    [No Abstract]   [Full Text] [Related]  

  • 26. [Basic and clinical studies of cefotiam in the field of pediatrics (author's transl)].
    Toyonaga Y; Kurosu Y; Hori M
    Jpn J Antibiot; 1981 May; 34(5):690-704. PubMed ID: 6270411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Estimation of level of aminoglycosides susceptibility of bacterial strains isolated from patients with systemic and general infections].
    Kowalska-Krochmal B; Dolna I; Dobosz A; Wrzyszcz E; Gościniak G
    Med Dosw Mikrobiol; 2008; 60(3):205-14. PubMed ID: 19143174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro- and in vivo- studies with aminoglycosides].
    Ritzerfeld W
    Adv Clin Pharmacol; 1978; 15():13-21. PubMed ID: 676872
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cocci carriers among patients at the Department of Dermatology. 3. Some factors influencing the occurrence of individual differences in the colonization of the skin by cocci].
    Kryński S; Dratwiński Z; Piskozub E; Becla E
    Przegl Dermatol; 1974; 61(4):489-93. PubMed ID: 4848312
    [No Abstract]   [Full Text] [Related]  

  • 30. [A clinical study on S6472, sustained release preparation of cefaclor, dermatological area].
    Kawanami T; Shibata A; Hanawa S; Morishima T
    Jpn J Antibiot; 1990 Sep; 43(9):1621-8. PubMed ID: 2262967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anti-bacterial effect of ofloxacin--in vitro and in vivo results].
    Altay G; Tulunay C
    Mikrobiyol Bul; 1985 Oct; 19(4):183-9. PubMed ID: 3868736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mupirocin-resistant Staphylococcus aureus.
    Lancet; 1987 Aug; 2(8555):387-8. PubMed ID: 2886836
    [No Abstract]   [Full Text] [Related]  

  • 33. [Comparative study of tobramycin and gentamicin].
    Klastersky J; Daneau D; Henri A
    Acta Clin Belg; 1972; 27(5):589-99. PubMed ID: 4205788
    [No Abstract]   [Full Text] [Related]  

  • 34. [Evaluation of susceptibility of methicillin resistant Staphylococcus aureus strains to vancomycin].
    Młynarczyk G; Młynarczyk A; Meisel-Mikołajczyk F
    Med Dosw Mikrobiol; 1995; 47(3-4):133-9. PubMed ID: 8833924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fundamental and clinical investigations of cefotaxime in neonates].
    Hashira S; Koike Y; Fujii R
    Jpn J Antibiot; 1982 Jul; 35(7):1737-48. PubMed ID: 6294355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Laboratory and clinical studies of cefoperazone in children (author's transl)].
    Iwai N; Sasaki A; Miyazu M; Osuga T; Inokuma K
    Jpn J Antibiot; 1980 Sep; 33(9):871-90. PubMed ID: 6452536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM; Barriere SL; Kitt MM; Benton BM
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):181-5. PubMed ID: 20846593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA; Nichol K; Zhanel GG
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
    Mendes RE; Sader HS; Jones RN
    Int J Antimicrob Agents; 2010 Oct; 36(4):374-9. PubMed ID: 20598860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The aminoglycosides.
    Whelton A
    Clin Orthop Relat Res; 1984 Nov; (190):66-74. PubMed ID: 6386262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.